Immunogenicity of coiled-coil based drug-free macromolecular therapeutics

Biomaterials

Volumn 35, Issue 22, 2014, Pages 5886-5896

  Kverka, Miloslav ^a,b   Hartley, Jonathan M ^c   Chu, Te Wei ^a   Yang, Jiyuan ^a   Heidchen, Regina ^a   Kopeček, Jindřich ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c University of Utah   (United States)

Author keywords

Coiled coil peptides; Drug free macromolecular therapeutics; Enantiomers; Fab' fragment; HPMA copolymer; Immunogenicity

Indexed keywords

ANTIBODIES; CELL DEATH; CELL MEMBRANES; ENANTIOMERS; MACROMOLECULES; MACROPHAGES; MAMMALS;

COILED COIL PEPTIDE; FAB' FRAGMENT; HPMA COPOLYMERS; IMMUNOGENICITY; MACROMOLECULAR THERAPEUTICS;

PEPTIDES;

DEXTRO CCE PEPTIDE; DEXTRO CCK PEPTIDE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLOGIC AGENT; LEVO CCE PEPTIDE; LEVO CCK PEPTIDE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; N-(2-HYDROXYPROPYL)METHACRYLAMIDE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BIOCOMPATIBILITY; CONJUGATE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG MEGADOSE; ENANTIOMER; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; LOW DRUG DOSE; MACROMOLECULE; MACROPHAGE ACTIVATION; MOLECULAR WEIGHT; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE; MOLECULAR GENETICS; T LYMPHOCYTE;

MUS;

ACRYLAMIDES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; CELL LINE; IMMUNOGLOBULIN FAB FRAGMENTS; MACROPHAGES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES;

EID: 84899898176     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.063     Document Type: Article

References (50)

1. Kopeček J., Yang J. Smart self-assembled hybrid hydrogel biomaterials. Angew Chem Int Ed Engl 2012, 51(30):7396-7417.
2. Kopeček J., Yang J. Peptide-directed self-assembly of hydrogels. Acta Biomater 2009, 5(3):805-816.
3. Yang J., Wu K., Koňák Č., Kopeček J. Dynamic light scattering study of self-assembly of HPMA hybrid graft copolymers. Biomacromolecules 2008, 9(2):510-517.
4. Yang J., Xu C., Wang C., Kopeček J. Refolding hydrogels self-assembled from N-(2-hydroxypropyl)methacrylamide graft copolymers by antiparallel coiled-coil formation. Biomacromolecules 2006, 7(4):1187-1195.
5. Hofmeister J.K., Cooney D., Coggeshall K.M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000, 26(2):133-143.
6. Zhang N., Khawli L.A., Hu P., Epstein A.L. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005, 11(16):5971-5980.
7. Wu K., Liu J., Johnson R.N., Yang J., Kopeček J. Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew Chem Int Ed Engl 2010, 49(8):1451-1455.
8. Wu K., Yang J., Liu J., Kopeček J. Coiled-coil based drug-free macromolecular therapeutics: invivo efficacy. JControl Release 2012, 157(1):126-131.
9. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2(8):469-478.
10. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23(9):1137-1146.
11. Korčáková L., Paluska E., Hašková V., Kopeček J. A simple test for immunogenicity of colloidal infusion solutions - the draining lymph node activation. ZImmunitätsforsch 1976, 151(3):219-223.
12. Říhová B., Ulbrich K., Kopeček J., Mančal P. Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers-potential hapten or drug carriers. Folia Microbiol (Praha) 1983, 28(3):217-227.
13. Říhová B., Bilej M., Větvička V., Ulbrich K., Strohalm J., Kopeček J., et al. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow invivo and mouse splenocytes and human peripheral blood lymphocytes invitro. Biomaterials 1989, 10(5):335-342.
14. Kopeček J. Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev 2013, 65(1):49-59.
15. Kopeček J., Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010, 62(2):122-149.
16. Vicent M.J., Ringsdorf H., Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev 2009, 61(13):1117-1120.
17. Goodman-Snitkoff G., Eisele L.E., Heimer E.P., Felix A.M., Andersen T.T., Fuerst T.R., et al. Defining minimal requirements for antibody production to peptide antigens. Vaccine 1990, 8(3):257-262.
18. Říhová B. Biocompatibility of biomaterials: hemocompatibility, immunocompatiblity and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv Drug Deliv Rev 1996, 21(2):157-176.
19. Říhová B., Kopeček J., Ulbrich K., Chytrý V. Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers. Makromol Chem 1985, (Suppl 9):13-24.
20. Rudra J.S., Tripathi P.K., Hildeman D.A., Jung J.P., Collier J.H. Immune responses to coiled coil supramolecular biomaterials. Biomaterials 2010, 31(32):8475-8483.
21. Gras-Masse H., Jolivet M., Drobecq H., Aubert J.P., Beachey E.H., Audibert F., et al. Influence of helical organization on immunogenicity and antigenicity of synthetic peptides. Mol Immunol 1988, 25(7):673-678.
22. Lu S.M., Hodges R.S. Ade novo designed template for generating conformation-specific antibodies that recognize alpha-helices in proteins. JBiol Chem 2002, 277(26):23515-23524.
23. Dintzis H.M., Symer D.E., Dintzis R.Z., Zawadzke L.E., Berg J.M. Acomparison of the immunogenicity of a pair of enantiomeric proteins. Proteins 1993, 16(3):306-308.
24. Chong P., Sia C., Tripet B., James O., Klein M. Comparative immunological properties of enantiomeric peptides. Lett Pept Sci 1996, 3(2):99-106.
25. Sela M., Zisman E. Different roles of d-amino acids in immune phenomena. FASEB J 1997, 11(6):449-456.
26. Mitsukami Y., Donovan M.S., Lowe A.B., McCormick C.L. Water-soluble polymers. 81. Direct synthesis of hydrophilic styrenic-based homopolymers and block copolymers in aqueous solution via RAFT. Macromolecules 2001, 34(7):2248-2256.
27. Kopeček J., Bažilová H. Poly[N-(2-hydroxypropyl)methacrylamide] - I. Radical polymerization and copolymerization. Eur Polym J 1973, 9(1):7-14.
28. Chu T.W., Yang J., Kopeček J. Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis. Biomaterials 2012, 33(29):7174-7181.
29. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82(1):70-77.
30. Starcher B. Aninhydrin-based assay to quantitate the total protein content of tissue samples. Anal Biochem 2001, 292(1):125-129.
31. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. JBiol Chem 1999, 274(16):10689-10692.
32. Wang W.W., Jenkinson C.P., Griscavage J.M., Kern R.M., Arabolos N.S., Byrns R.E., et al. Co-induction of arginase and nitric oxide synthase in murine macrophages activated by lipopolysaccharide. Biochem Biophys Res Commun 1995, 210(3):1009-1016.
33. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374(Pt 1):1-20.
34. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-238.
35. Clahsen T., Schaper F. Interleukin-6 acts in the fashion of a classical chemokine on monocytic cells by inducing integrin activation, cell adhesion, actin polymerization, chemotaxis, and transmigration. JLeukoc Biol 2008, 84(6):1521-1529.
36. Pedra J.H., Cassel S.L., Sutterwala F.S. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol 2009, 21(1):10-16.
37. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23(11):549-555.
38. Pelegrin P., Barroso-Gutierrez C., Surprenant A. P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. JImmunol 2008, 180(11):7147-7157.
39. Scheibel M., Klein B., Merkle H., Schulz M., Fritsch R., Greten F.R., et al. IkappaBbeta is an essential co-activator for LPS-induced IL-1beta transcription invivo. JExp Med 2010, 207(12):2621-2630.
40. Kim J.K., Lee S.M., Suk K., Lee W.H. Anovel pathway responsible for lipopolysaccharide-induced translational regulation of TNF-alpha and IL-6 expression involves protein kinase C and fascin. JImmunol 2011, 187(12):6327-6334.
41. Radtke S., Wuller S., Yang X.P., Lippok B.E., Mutze B., Mais C., et al. Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. JCell Sci 2010, 123(Pt 6):947-959.
42. Peroval M.Y., Boyd A.C., Young J.R., Smith A.L. Acritical role for MAPK signalling pathways in the transcriptional regulation of toll like receptors. PLoS One 2013, 8(2):e51243.
43. Lei M., Jiao H., Liu T., Du L., Cheng Y., Zhang D., et al. siRNA targeting mCD14 inhibits TNF-alpha, MIP-2, and IL-6 secretion and NO production from LPS-induced RAW264.7 cells. Appl Microbiol Biotechnol 2011, 92(1):115-124.
44. Jeannin P., Delneste Y., Buisine E., Le Mao J., Didierlaurent A., Stewart G.A., et al. Immunogenicity and antigenicity of synthetic peptides derived from the mite allergen Der p I. Mol Immunol 1993, 30(16):1511-1518.
45. Dintzis H.M., Dintzis R.Z., Vogelstein B. Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci U S A 1976, 73(10):3671-3675.
46. Lymberi P., Blancher A., Calvas P., Avrameas S. Natural autoantibodies in nude and normal outbred (Swiss) and inbred (BALB/c) mice. JAutoimmun 1989, 2(3):283-295.
47. Jensen P.E., Kapp J.A. Bystander help in primary immune responses invivo. JExp Med 1986, 164(3):841-854.
48. Johnson T.A., Press O.W. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol 2000, 79(4):175-182.
49. Press O.W., Appelbaum F., Ledbetter J.A., Martin P.J., Zarling J., Kidd P., et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987, 69(2):584-591.
50. van Dam G.J., Verheul A.F., Zigterman G.J., de Reuver M.J., Snippe H. Estimation of the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 by inhibition ELISA. Mol Immunol 1989, 26(3):269-274.